heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-02. Anything still debated is marked as such rather than presented as settled.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
| Property | Value | Notes |
|---|---|---|
| Dry storage temperature | -20 C or below | Sealed, desiccated, protected from light |
| Solution stability | Hours to days at 2-8 C | Depends on buffer and microbial load |
| Preferred pH range | Near neutral to slightly acidic | Alkaline pH accelerates hydrolysis |
| Main degradation routes | Hydrolysis and deamidation | No cysteine or methionine in sequence |
| Identity confirmation | Electrospray mass spectrometry | Observed mass compared with 751.9 Da |
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
== Advocacy == Breakthrough T1D advocates for federally funded T1D research, facilitates the delivery of medical advancements and resources to the T1D community, and supports policies that help prevent, manage, and treat T1D, with an aim toward eventual development of a cure. Breakthrough T1D has advocated for various kinds of research; in a 2004 article in The Wall Street Journal, the authors observed that the Breakthrough T1D "... has become adept at unleashing an army of hard-to-resist lobbyists – made up of determined parents and their afflicted children – on researchers, politicians and potential donors."
Rebellions in the former Cossack territories erupted occasionally during the interwar period. In 1920–1921, disgruntlement with continued Soviet grain-requisitioning activities provoked a series of revolts among Cossack and outlander communities in South Russia. The former Cossack territories of South Russia and the Urals also experienced a devastating famine in 1921–1922. In 1932–1933, another famine, known as the Holodomor, devastated Ukraine and some parts of South Russia, causing a population decline of about 20–30%. While urban areas were less affected, the decline was even higher in the rural areas, populated largely by Cossacks. Robert Conquest estimates the number of famine-related deaths in the Northern Caucasus at about one million. Government officials expropriated grain and other produce from rural Cossack families, leaving them to starve and die. Many families were forced from their homes in the severe winter and froze to death. Mikhail Sholokhov's letters to Joseph Stalin document the conditions and widespread deaths, as do eyewitness accounts. Besides starvation, the collectivization and dekulakization campaigns of the early 1930s threatened Cossacks with deportation to labor camps, or outright execution by Soviet security organs. In April 1936, the Soviet regime began to relax its restrictions on Cossacks, allowing them to serve openly in the Red Army. Two existing cavalry divisions were renamed as Cossack divisions, and three new Cossack cavalry divisions were established.
Ball JC, Vander Jagt DL (1979). "Purification of S-2-hydroxyacylglutathione hydrolase (glyoxalase II) from rat erythrocytes". Anal. Biochem. 98 (2): 472–7. doi:10.1016/0003-2697(79)90169-6. PMID 496013.
Sources: en.wikipedia.org
Pelage Pharmaceuticals presented on suvomipic at the American Academy of Dermatology (AAD) Annual Meeting 2026 in March 2026, including disclosing some new phase 2a trial data, but did not provide the open-label extension data at this event. Phase 3 trials of suvomipic for alopecia are being planned for 2026. It has been estimated that if suvomipic is successful in clinical trials and passes regulatory scrutiny, the drug could be approved for the treatment of hair loss sometime between 2027 and 2029 at the earliest. Suvomipic is currently Pelage Pharmaceuticals's only official drug candidate. However, the company is also investigating reactivation of dormant stem cells for treatment of other medical conditions. Pelage Pharmaceuticals had raised more than $30 million by August 2025, with investment being led by Google Ventures of Alphabet. In October 2025, it was announced that the company had raised $120 million. In 2019, Pelage Pharmaceuticals had reached an agreement that granted Allergan (now AbbVie) an option to acquire the startup company, but this deal was terminated in 2020. Suvomipic may also have applications in the treatment of other forms of hair loss besides androgenic alopecia. In October 2025, Time magazine named suvomipic one of the best inventions of 2025. However, the magazine also disclosed, via communication with Pelage Pharmaceuticals, that suvomipic may not be effective in the end stages of balding if the hair follicle is "scarred".
=== Genetics === Alport syndrome is caused by mutations in COL4A3, COL4A4, and COL4A5, three of six human genes involved in basement membrane (type IV) collagen biosynthesis. Mutations in any of these genes prevent the proper production or assembly of the specialised type IV collagen '345' network which is an important structural component of basement membranes in the kidney, inner ear, and eye. It is also found in other locations, including the alveoli of the lungs. Basement membranes are thin, sheet-like structures that separate and support cells in many tissues. Type IV collagen '112' type is found in both vertebrates and invertebrates and is the major isoform in most human basement membranes. When mutations prevent the formation of 345 type IV collagen network in the glomerulus, the 112 network, which is formed in fetal development but usually replaced by 345, persists into adult life.
In contrast with EOD, the incidence of LOD has remained unchanged at 0.24-0.26 per 1000 live births in the US. S. agalactiae neonatal meningitis does not present with the hallmark sign of adult meningitis, a stiff neck; rather, it presents with nonspecific symptoms, such as fever, vomiting, and irritability, and can consequently lead to a late diagnosis.
Sources: en.wikipedia.org
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.
Hydrolysis of peptide bonds and deamidation of arginine and proline residues are the main degradation routes. Alkaline pH and higher temperatures accelerate both processes. Buffered, near-neutral solutions stored cold generally degrade more slowly than unbuffered ones.
Reverse-phase chromatography gives the clearest single view of related impurities and truncated sequences. Mass spectrometry then confirms that the main peak carries the expected mass. Neither test detects enantiomeric impurities, which require a separate chiral assay.
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.